Abbott announces its intention to separate its global Nutrition business into an independent, publicly traded company
Abbott announced its intention to separate its global Nutrition business — roughly $8.5 billion in annual sales — into an independent, publicly traded company via a tax-free distribution to shareholders. The new company will house iconic brands including Similac, PediaSure, Pedialyte, Glucerna and Ensure, led by incoming CEO Daniel Salvadori, with about 16,000 employees and 14 manufacturing sites. Post-separation Abbott will retain a ~$42 billion sales portfolio focused on medical devices, biowearables, diagnostics and established medicines, and expects to complete the deal by the end of 2027 subject to regulatory approvals, a Form 10 and board approval.
Key figures
- Dividend
- combined dividend of Abbott plus new Nutrition company to equal Abbott's dividend at time of separation
- Expected completion
- end of 2027
- Nutrition employees
- 16000
- Transaction structure
- tax-free distribution of Nutrition company shares to Abbott shareholders
- Nutrition annual sales
- 8500000000
- Post separation abt sales
- 42000000000
- Nutrition manufacturing sites
- 14
- Post separation abt employees
- 106000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.